[3] Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors.

[4] Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500.

[6] The company expected sales of its drug Cubicin to grow to more than 1 billion dollars per year.

[7] In 2014, succeeding Michael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015.

The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides.